Drug intelligence / Profile preview

2,4-deoxy-4-guanidino-5-N-acetyl-neuraminic acid

Development stage
Preclinical
Lead developer
GSK
Modality
Small Molecules
01

Overview

**Description:**\n*2,4-deoxy-4-Guanidino–5-N-acetyl–neuraminic acid* is a synthetic analogue of sialic acids and a member of the neuraminic acid derivative class. It is an experimental compound that acts as an inhibitor of viral neuraminidase enzymes. Neuraminidases catalyze the removal of terminal sialic acids from glycoproteins and glycolipids on host cells and viruses—a process essential for viral replication and release. By inhibiting this enzyme’s activity in influenza viruses (and potentially other pathogens), this compound can block virus spread by preventing efficient budding and cell-to-cell transmission[3][8]. Its mechanism is similar to that of zanamivir but with structural differences at specific positions on the sugar ring. The compound has been studied primarily in vitro as a research tool for understanding neuraminidase function; it has not reached clinical development or approval stages.

Other names
(2R,4S,5R,6R)-5-Acetamido-4-(diaminomethylideneamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid(2R,4S,5R,6R)-4-((diaminomethylidene)amino)-5-acetamido-6-((1R,2R)-1,2,3-trihydroxypropyl)oxane-2-carboxylic acid(2R,4S,5R,6R)-4-[(diaminomethylidene)amino]-5-acetamido-6-(1R,2R)-1-, 2-, 3-trihydroxypropyl]oxane -carboxylic acid
02

Targets

Neuraminidase

Beyond the preview

Go deeper on 2,4-deoxy-4-guanidino-5-N-acetyl-neuraminic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2,4-deoxy-4-guanidino-5-N-acetyl-neuraminic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call